Josep Maria Piulats is the group leader of the Clinical Research in Solid Tumours group of Oncobell, within Idibell. His group is striving to become the gateway to purely translational/clinical research generated at the ICO and the academic pathway to introducing new treatments. The team’s aim is to transform ideas and hypotheses generated in the…
Read More
LECTURE: He is going to talk about Targeting the IRBC in c-Myc driven tumors in the first Oncobell Symposium. BIOGRAPHY: George Thomas is acknowledged as an innovative leader in the field of signal transduction and growth control based on his seminal studies on the discovery and regulation of the 40S ribosomal protein S6 kinase (S6K1), and more…
Read More
Joan Seoane is a Group Leader and Director of the Translational Research program at the Vall d’Hebron Institute of Oncology (VHIO) within the Vall d’Hebron University Hospital since 2011. In 1998, Joan obtained his PhD in Biochemistry and Molecular Biology from the University of Barcelona. Previously, in 1993, he obtained his BSc degree in Chemistry.…
Read More
Victor Moreno is group leader of the Colorectal Cancer Group at Oncobell, Professor of Preventive Medicine at the University of Barcelona and Director of the Cancer Prevention and Control Program at the Catalan Institute of Oncology. His main research area is cancer prevention, with special interest in colorectal cancer (CRC). He performs studies on genetic and molecular epidemiology aiming to…
Read More
Prof. Mark Rubin is a leader in the fields of prostate cancer biology and precision medicine as it applies to all cancers. Rubin’s laboratory led a series of landmark studies defining distinct molecular features of prostate cancer, revealing pathways that are perturbed and drive different types of this cancer. Prof. Rubin has translated many of…
Read More
Isabel Fabregat is Senior Investigator, head of the “TGF-β and Cancer” group at IDIBELL and part-time Associate Professor in the University of Barcelona. The current research line of her laboratory focuses on the dissection of the molecular mechanisms induced by Transforming Growth Factor-beta (TGF-β) in liver cells that can explain its different, and sometimes opposite,…
Read More
Elias Campo received his MD and PhD degrees from the Medical School at the University of Barcelona. He was a post-doctoral researcher at the Laboratory of Pathology, National Cancer Institute, Bethesda, MD. He is currently Professor of Pathology and Chief of the Hematopathology Unit at the Hospital Clinic of Barcelona, University of Barcelona. His research…
Read More
Anna Sureda, (MD, PhD) is nowadays the Head of the Clinical Hematology Department of Institut Català d’Oncologia – Hospitalet, Barcelona. She had previously been a senior consultant in Hospital de la Santa Creu I Sant Pau, Barcelona and a senior consultant focused in lymphomas and hematopoietic stem cell transplantation in Cambridge, UK. She was a…
Read More
René Bernards is a professor of molecular carcinogenesis at the Netherlands Cancer Institute. His laboratory uses functional genomic approaches to find vulnerabilities of cancers that can be exploited therapeutically. Using the concept of synthetic lethality, his laboratory searches for combinations of drugs that are lethal for cancer cells and for vulnerabilities of cancer cells of…
Read More
Cristina Muñoz Pinedo, leader of Cell Death Regulation Group at Oncobell will chair Targeting of Signaling Pathways table in the next Oncobell Symposium. Cristina Muñoz-Pinedo’s group researches the mechanisms through which tumour cells die in response to different treatments, and to glucose metabolism inhibition in particular. It studies the responses both at the cell level…
Read More